muramidase and Epstein-Barr-Virus-Infections

muramidase has been researched along with Epstein-Barr-Virus-Infections* in 3 studies

Other Studies

3 other study(ies) available for muramidase and Epstein-Barr-Virus-Infections

ArticleYear
Epstein-Barr virus LMP2A imposes sensitivity to apoptosis.
    The Journal of general virology, 2010, Volume: 91, Issue:Pt 9

    In cell lines, the Epstein-Barr virus (EBV)-encoded protein latent membrane protein 2A (LMP2A) protects B-cells from apoptosis by blocking B-cell receptor (BCR) signalling. However, EBV-infected B-cells in vivo are extremely different from cell lines. This study used a murine transgenic model in which B-cells express LMP2A and a BCR specific for hen egg lysozyme to determine whether LMP2A protects resting and antigen-activated B-cells from apoptosis. LMP2A allows BCR signal transduction and induces constitutive activation of NF-kappaB to increase Bcl-2 levels that afford LMP2A-mediated protection from apoptosis in the absence or presence of antigen. In contrast, low levels of NF-kappaB inhibitor only affected Bcl-2 and Bcl-xL levels and increased apoptosis in LMP2A-negative B-cells after BCR cross-linking. These data suggest that LMP2A uniquely makes resting B-cells sensitive to NF-kappaB inhibition and apoptosis and suggest that NF-kappaB may be a novel target to eradicate latently EBV-infected B-cells.

    Topics: Animals; Antigens; Apoptosis; B-Lymphocytes; Epstein-Barr Virus Infections; Herpesvirus 4, Human; In Vitro Techniques; Mice; Mice, Transgenic; Muramidase; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Receptors, Antigen, B-Cell; Recombinant Proteins; Signal Transduction; Viral Matrix Proteins

2010
Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro.
    Journal of virology, 2006, Volume: 80, Issue:14

    Epstein-Barr virus (EBV) establishes latent infections in a significant percentage of the population. Latent membrane protein 2A (LMP2A) is an EBV protein expressed during latency that inhibits B-cell receptor signaling in lymphoblastoid cell lines. In the present study, we have utilized a transgenic mouse system in which LMP2A is expressed in B cells that are specific for hen egg lysozyme (E/HEL-Tg). To determine if LMP2A allows B cells to respond to antigen, E/HEL-Tg mice were immunized with hen egg lysozyme. E/HEL-Tg mice produced antibody in response to antigen, indicating that LMP2A allows B cells to respond to antigen. In addition, E/HEL-Tg mice produced more antibody and an increased percentage of plasma cells after immunization compared to HEL-Tg littermates, suggesting that LMP2A increased the antibody response in vivo. Finally, in vitro studies determined that LMP2A acts directly on the B cell to increase antibody production by augmenting the expansion and survival of the activated B cells, as well as increasing the percentage of plasma cells generated. Taken together, these data suggest that LMP2A enhances, not diminishes, B-cell-specific antibody responses in vivo and in vitro in the E/HEL-Tg system.

    Topics: Animals; Antibody Formation; Antigens; Cell Differentiation; Cell Line, Tumor; Cell Survival; Epstein-Barr Virus Infections; Female; Lymphocyte Activation; Male; Mice; Mice, Transgenic; Muramidase; Plasma Cells; Transgenes; Viral Matrix Proteins

2006
Immunocytochemical localization of lysozyme and lactoferrin attached to surface bacteria of the palatine tonsils during infectious mononucleosis.
    The Journal of laryngology and otology, 2002, Volume: 116, Issue:4

    Bacterial samples were obtained from the tonsillar surfaces of seven patients (four males, three females; median age 18 years, range 15 to 21 years) suffering from acute infectious mononucleosis with concomitant pharyngotonsillitis, and from five healthy controls. By using gold-labelled antiserum to human lysozyme and lactoferrin, micro-organisms on the tonsillar surfaces coated with these antibacterial substances could be identified by tracing the gold particles in the transmission electron microscope. In healthy individuals, most of the bacteria were coated with lysozyme and significantly more bacteria were coated with lysozyme than with lactoferrin (p < 0.01). In patients there was a non-significant reduction in lysozyme-coating of the bacteria, whereas lactoferrin-coating was significantly increased (p < 0.01). Changes in the lysozyme and/or lactoferrin coating of the tonsillar surface bacteria on the palatine tonsils during infectious mononucleosis cannot explain the tendency to immense local bacterial colonization with commensals and proneness to bacterial penetration into the epithelial cells.

    Topics: Adolescent; Adult; Bacteria; Bacterial Infections; Epstein-Barr Virus Infections; Female; Humans; Immunohistochemistry; Lactoferrin; Male; Muramidase; Palatine Tonsil; Statistics, Nonparametric; Tonsillitis

2002